Assets
(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Revefenacin(Yupelri) | Approved | Muscarinic receptors (antagonist)Small molecule | Chronic Obstructive Pulmonary Disease |
| Phase 3 | norepinephrine transporterSmall molecule | Neurogenic Orthostatic Hypotension |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.